No data to show
XLON
FDBK
Market cap8mUSD
Jul 25, Last price
14.50GBP
1D
0.00%
1Q
-17.14%
Jan 2017
-96.56%
Name
Feedback PLC
Chart & Performance
P/E
—
P/S
537.70
EPS
—
Div Yield, %
—
Shrs. gr., 5y
51.05%
Rev. gr., 5y
15.98%
Revenues
1m
+15.27%
Net income
-3m
L+13.03%
CFO
-2m
L+22.08%
Dividend
Jul 10, 19950.4959 GBP/sh
Earnings
Sep 03, 2025
Profile
Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a patent-protected software tool, which extracts and quantifies texture features in radiological images, assists research into all tumour types, and uncovers biomarkers in medical images; and TexRAD Lung, a software tool for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, a secure clinical communications platform that facilitates the sharing of clinical-grade medical images. Feedback plc was incorporated in 1958 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2016‑05 | |
| Income | |||||||||
Revenues | 1,182 15.27% | 1,025 74.15% | |||||||
Cost of revenue | 1,037 | 1,675 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 145 | (650) | |||||||
NOPBT Margin | 12.26% | ||||||||
Operating Taxes | (299) | (456) | |||||||
Tax Rate | |||||||||
NOPAT | 443 | (194) | |||||||
Net income | (3,298) 13.03% | (2,918) 37.74% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 10,490 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (3,878) | (7,318) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (2,127) | (1,743) | |||||||
CAPEX | (1,313) | (1,245) | |||||||
Cash from investing activities | (1,313) | (1,245) | |||||||
Cash from financing activities | (830) | ||||||||
FCF | 445 | (94) | |||||||
| Balance | |||||||||
Cash | 3,878 | 7,318 | |||||||
Long term investments | |||||||||
Excess cash | 3,818 | 7,266 | |||||||
Stockholders' equity | (8,398) | (4,481) | |||||||
Invested Capital | 16,043 | 15,203 | |||||||
ROIC | 2.84% | ||||||||
ROCE | 1.89% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 13,335 | 13,335 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 1,102 | 159 | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||